Zydus Cadila gets USFDA nod for multiple sclerosis drug Fingolimod
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis.
Ahmedabad: Pharma major, Zydus Cadila, has recently announced that the company has received tentative approval from the United States Food & Drug Administration (USFDA) to market Fingolimod Capsules in the strength of .25 mg (US RLD: Gilenya Capsules).
Earlier, in October 2020, the group was granted approval to market Fingolimod Capsules in the strength of .5mg.
Fingolimod is an immunomodulating drug.
It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila may seek DCGI nod for ZyCoV-D next week: Report
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd